0001104659-19-036506.txt : 20190619
0001104659-19-036506.hdr.sgml : 20190619
20190619213929
ACCESSION NUMBER: 0001104659-19-036506
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190617
FILED AS OF DATE: 20190619
DATE AS OF CHANGE: 20190619
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CARPENTER CHRISTOPHER L.
CENTRAL INDEX KEY: 0001746845
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38586
FILM NUMBER: 19907359
MAIL ADDRESS:
STREET 1: C/O RUBIUS THERAPEUTICS
STREET 2: 325 VASSAR ST., SUITE 1A
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Rubius Therapeutics, Inc.
CENTRAL INDEX KEY: 0001709401
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 042688109
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 399 BINNEY STREET, SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-679-9600
MAIL ADDRESS:
STREET 1: 399 BINNEY STREET, SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
a4.xml
4
X0306
4
2019-06-17
0
0001709401
Rubius Therapeutics, Inc.
RUBY
0001746845
CARPENTER CHRISTOPHER L.
C/O RUBIUS THERAPEUTICS, INC.
399 BINNEY STREET, SUITE 300
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
Common Stock
2019-06-17
4
M
0
18500
2.87
A
53343
D
Common Stock
2019-06-17
4
S
0
18500
14.1010
D
34843
D
Common Stock
2019-06-18
4
M
0
10858
2.87
A
45701
D
Common Stock
2019-06-18
4
S
0
10858
14.2713
D
34843
D
Common Stock
2019-06-19
4
M
0
18399
2.87
A
53242
D
Common Stock
2019-06-19
4
S
0
18399
13.7979
D
34843
D
Stock Option (Right to Buy)
2.87
2019-06-17
4
M
0
18500
0
D
2027-10-24
Common Stock
18500
648657
D
Stock Option (Right to Buy)
2.87
2019-06-18
4
M
0
10858
0
D
2027-10-24
Common Stock
10858
637799
D
Stock Option (Right to Buy)
2.87
2019-06-19
4
M
0
18399
0
D
2027-10-24
Common Stock
18399
619400
D
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.40 to $14.42, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.11 to $14.56, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.68 to $14.21, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
25% of this option shall vest on September 18, 2018, then in 12 equal quarterly installments thereafter.
/s/ Joanne M. Protano, Attorney-in-Fact
2019-06-19